Edgewise Therapeutics Q4 net loss widens vs Q3 as costs rise

Edgewise Therapeutics

26/02/2026 13:11

Overview

Muscle disease biopharma's Q4 net loss widens from Q3 to $50.2 mln, with increased operating expenses

Company's R&D expenses rose due to personnel and clinical trial costs

Edgewise advances muscular dystrophy and cardiovascular programs with key trials in 2026

Outlook

Edgewise expects CIRRUS-HCM 12-week data for EDG-7500 in H1 2026

Company plans Phase 3 trial initiation for EDG-7500 in HCM in H2 2026

Edgewise anticipates GRAND CANYON trial data in Becker in Q4 2026

Result Drivers

R&D EXPENSES - Increase driven by personnel costs and clinical trial activities for EDG-15400 and EDG-7500

MUSCULAR DYSTROPHY PROGRAM - Advancing trials for sevasemten in Becker and Duchenne muscular dystrophies

CARDIOVASCULAR PROGRAMS - Progressing CIRRUS-HCM and EDG-15400 trials with key data expected in 2026

Company press release: ID:nPn4QbXrwa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Net Income
-$50.22 mln
Q4 Basic EPS
-$0.47
Q4 Operating Expenses
$55.98 mln
Q4 Operating Income
-$55.98 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Edgewise Therapeutics Inc is $41.50, about 37.8% above its February 25 closing price of $30.12

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)